Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Marlio Charles Mosseri Purchases 240,000 Shares

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri purchased 240,000 shares of the stock in a transaction dated Friday, February 7th. The stock was bought at an average cost of $5.00 per share, with a total value of $1,200,000.00. Following the completion of the purchase, the insider now owns 2,884,121 shares in the company, valued at $14,420,605. The trade was a 9.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Friday, December 13th, Marlio Charles Mosseri acquired 17,000 shares of Nuvectis Pharma stock. The shares were purchased at an average price of $4.70 per share, with a total value of $79,900.00.

Nuvectis Pharma Price Performance

NVCT traded down $0.04 during mid-day trading on Tuesday, hitting $6.29. The stock had a trading volume of 54,546 shares, compared to its average volume of 119,724. The stock’s fifty day simple moving average is $5.63 and its 200-day simple moving average is $6.34. The firm has a market capitalization of $121.52 million, a price-to-earnings ratio of -5.42 and a beta of 0.22. Nuvectis Pharma, Inc. has a 1-year low of $4.44 and a 1-year high of $12.10.

Institutional Trading of Nuvectis Pharma

Hedge funds have recently added to or reduced their stakes in the business. GSA Capital Partners LLP boosted its holdings in shares of Nuvectis Pharma by 3.7% in the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock valued at $315,000 after buying an additional 1,790 shares during the period. Nations Financial Group Inc. IA ADV lifted its position in Nuvectis Pharma by 35.0% in the 4th quarter. Nations Financial Group Inc. IA ADV now owns 13,500 shares of the company’s stock valued at $73,000 after acquiring an additional 3,500 shares in the last quarter. Forbes J M & Co. LLP raised its stake in shares of Nuvectis Pharma by 21.9% in the 4th quarter. Forbes J M & Co. LLP now owns 59,000 shares of the company’s stock valued at $319,000 after purchasing an additional 10,599 shares during the period. Oppenheimer & Co. Inc. bought a new stake in Nuvectis Pharma in the 4th quarter valued at approximately $135,000. Finally, Geode Capital Management LLC grew its stake in shares of Nuvectis Pharma by 49.8% during the 3rd quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock worth $501,000 after acquiring an additional 26,489 shares in the last quarter. Institutional investors and hedge funds own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.